Autifony Therapeutics awarded £2.2 million to progress first-in-class drug for tinnitus into Phase IIa study

  • Award follows successful completion of Phase I

London – UK – 4 June 2014 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced that it has been awarded funding of £2.2 million towards a Phase IIa clinical trial in tinnitus patients with its lead compound AUT00063, by the UK’s innovation agency, the Technology Strategy Board. Autifony will be sponsor of the clinical study, with Professor Deborah Hall at The University of Nottingham and National Institute for Health Research (NIHR) Nottingham Hearing Biomedical Research Unit (BRU) as lead academic collaborator.

Read more (103 kB)